Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms

Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management. Yet, a preventive or curative panacea for sustained AF does not exist...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2020-11, Vol.11, p.581837
Main Authors: Geng, Meng, Lin, Andrew, Nguyen, Thao P
Format: Article
Language:English
Subjects:
a-fib
afib
antiarrhythmic
antiarrhythmic drug therapy
atrial fibrillation
paroxysmal AF
Pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c531t-26002fc5d896da4588aa3685737012008b7a57c080ce4a7fbbf60beffabd3c533
cites cdi_FETCH-LOGICAL-c531t-26002fc5d896da4588aa3685737012008b7a57c080ce4a7fbbf60beffabd3c533
container_end_page
container_issue
container_start_page 581837
container_title Frontiers in pharmacology
container_volume 11
creator Geng, Meng
Lin, Andrew
Nguyen, Thao P
description Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management. Yet, a preventive or curative panacea for sustained AF does not exist despite the rise of AF global prevalence to epidemiological proportions. While multiple elevated risk factors for AF have been established, the natural history and etiology of AF remain incompletely understood. In the present article, the first section selectively highlights some disappointing shortcomings and current efforts in antiarrhythmic drug therapy to uncover reasons why AF is such a clinical challenge. The second section discusses some modern takes on the natural history of AF as a relentless, progressive fibro-inflammatory "atriomyopathy." The final section emphasizes the need to redefine therapeutic strategies on par with new insights of AF pathophysiology.
doi_str_mv 10.3389/fphar.2020.581837
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3fac155fa09548809d0c52169b84fa00</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3fac155fa09548809d0c52169b84fa00</doaj_id><sourcerecordid>2464605807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c531t-26002fc5d896da4588aa3685737012008b7a57c080ce4a7fbbf60beffabd3c533</originalsourceid><addsrcrecordid>eNpVkk1v1DAQhiMEolXpD-CCcuSyyziOHYcD0qrQUmklECpna-KPxFXiLHZStBd-e52mVK0vY83M-8zIfrPsPYEtpaL-ZA8dhm0BBWyZIIJWr7JTwjnd1IIUr5_dT7LzGG8hHVrXlJdvsxNKixKghtPs3y9z56KbnG_znZ8chtAdp25wKv8a5ja_6UzAwzG3Y8h3U3DY55euCa7vcXKj_5wvevN3ke9NjKOPKWLwRufodapqY51fyivJzFNC_8SA2rVDfJe9sdhHc_4Yz7Lfl99uLr5v9j-uri92-41ilEybggMUVjEtaq6xZEIgUi5YRSsgBYBoKmSVAgHKlFjZprEcGmMtNpomBD3LrleuHvFWHoIbMBzliE4-JMbQSgxps95IalERxixCzUohoNagWEF43YgyJSGxvqysw9wMRivjp4D9C-jLinedbMc7WXEBgvEE-PgICOOf2cRJDi4qk57Um3GOsih5yYEJqFIrWVtVGGMMxj6NISAXG8gHG8jFBnK1QdJ8eL7fk-L_p9N7E6extw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2464605807</pqid></control><display><type>article</type><title>Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms</title><source>PubMed Central</source><creator>Geng, Meng ; Lin, Andrew ; Nguyen, Thao P</creator><creatorcontrib>Geng, Meng ; Lin, Andrew ; Nguyen, Thao P</creatorcontrib><description>Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management. Yet, a preventive or curative panacea for sustained AF does not exist despite the rise of AF global prevalence to epidemiological proportions. While multiple elevated risk factors for AF have been established, the natural history and etiology of AF remain incompletely understood. In the present article, the first section selectively highlights some disappointing shortcomings and current efforts in antiarrhythmic drug therapy to uncover reasons why AF is such a clinical challenge. The second section discusses some modern takes on the natural history of AF as a relentless, progressive fibro-inflammatory "atriomyopathy." The final section emphasizes the need to redefine therapeutic strategies on par with new insights of AF pathophysiology.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2020.581837</identifier><identifier>PMID: 33240090</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>a-fib ; afib ; antiarrhythmic ; antiarrhythmic drug therapy ; atrial fibrillation ; paroxysmal AF ; Pharmacology</subject><ispartof>Frontiers in pharmacology, 2020-11, Vol.11, p.581837</ispartof><rights>Copyright © 2020 Geng, Lin and Nguyen.</rights><rights>Copyright © 2020 Geng, Lin and Nguyen Geng, Lin and Nguyen</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c531t-26002fc5d896da4588aa3685737012008b7a57c080ce4a7fbbf60beffabd3c533</citedby><cites>FETCH-LOGICAL-c531t-26002fc5d896da4588aa3685737012008b7a57c080ce4a7fbbf60beffabd3c533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680856/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680856/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33240090$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geng, Meng</creatorcontrib><creatorcontrib>Lin, Andrew</creatorcontrib><creatorcontrib>Nguyen, Thao P</creatorcontrib><title>Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management. Yet, a preventive or curative panacea for sustained AF does not exist despite the rise of AF global prevalence to epidemiological proportions. While multiple elevated risk factors for AF have been established, the natural history and etiology of AF remain incompletely understood. In the present article, the first section selectively highlights some disappointing shortcomings and current efforts in antiarrhythmic drug therapy to uncover reasons why AF is such a clinical challenge. The second section discusses some modern takes on the natural history of AF as a relentless, progressive fibro-inflammatory "atriomyopathy." The final section emphasizes the need to redefine therapeutic strategies on par with new insights of AF pathophysiology.</description><subject>a-fib</subject><subject>afib</subject><subject>antiarrhythmic</subject><subject>antiarrhythmic drug therapy</subject><subject>atrial fibrillation</subject><subject>paroxysmal AF</subject><subject>Pharmacology</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkk1v1DAQhiMEolXpD-CCcuSyyziOHYcD0qrQUmklECpna-KPxFXiLHZStBd-e52mVK0vY83M-8zIfrPsPYEtpaL-ZA8dhm0BBWyZIIJWr7JTwjnd1IIUr5_dT7LzGG8hHVrXlJdvsxNKixKghtPs3y9z56KbnG_znZ8chtAdp25wKv8a5ja_6UzAwzG3Y8h3U3DY55euCa7vcXKj_5wvevN3ke9NjKOPKWLwRufodapqY51fyivJzFNC_8SA2rVDfJe9sdhHc_4Yz7Lfl99uLr5v9j-uri92-41ilEybggMUVjEtaq6xZEIgUi5YRSsgBYBoKmSVAgHKlFjZprEcGmMtNpomBD3LrleuHvFWHoIbMBzliE4-JMbQSgxps95IalERxixCzUohoNagWEF43YgyJSGxvqysw9wMRivjp4D9C-jLinedbMc7WXEBgvEE-PgICOOf2cRJDi4qk57Um3GOsih5yYEJqFIrWVtVGGMMxj6NISAXG8gHG8jFBnK1QdJ8eL7fk-L_p9N7E6extw</recordid><startdate>20201109</startdate><enddate>20201109</enddate><creator>Geng, Meng</creator><creator>Lin, Andrew</creator><creator>Nguyen, Thao P</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20201109</creationdate><title>Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms</title><author>Geng, Meng ; Lin, Andrew ; Nguyen, Thao P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c531t-26002fc5d896da4588aa3685737012008b7a57c080ce4a7fbbf60beffabd3c533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>a-fib</topic><topic>afib</topic><topic>antiarrhythmic</topic><topic>antiarrhythmic drug therapy</topic><topic>atrial fibrillation</topic><topic>paroxysmal AF</topic><topic>Pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geng, Meng</creatorcontrib><creatorcontrib>Lin, Andrew</creatorcontrib><creatorcontrib>Nguyen, Thao P</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geng, Meng</au><au>Lin, Andrew</au><au>Nguyen, Thao P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2020-11-09</date><risdate>2020</risdate><volume>11</volume><spage>581837</spage><pages>581837-</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management. Yet, a preventive or curative panacea for sustained AF does not exist despite the rise of AF global prevalence to epidemiological proportions. While multiple elevated risk factors for AF have been established, the natural history and etiology of AF remain incompletely understood. In the present article, the first section selectively highlights some disappointing shortcomings and current efforts in antiarrhythmic drug therapy to uncover reasons why AF is such a clinical challenge. The second section discusses some modern takes on the natural history of AF as a relentless, progressive fibro-inflammatory "atriomyopathy." The final section emphasizes the need to redefine therapeutic strategies on par with new insights of AF pathophysiology.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>33240090</pmid><doi>10.3389/fphar.2020.581837</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2020-11, Vol.11, p.581837
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3fac155fa09548809d0c52169b84fa00
source PubMed Central
subjects a-fib
afib
antiarrhythmic
antiarrhythmic drug therapy
atrial fibrillation
paroxysmal AF
Pharmacology
title Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A48%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revisiting%20Antiarrhythmic%20Drug%20Therapy%20for%20Atrial%20Fibrillation:%20Reviewing%20Lessons%20Learned%20and%20Redefining%20Therapeutic%20Paradigms&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Geng,%20Meng&rft.date=2020-11-09&rft.volume=11&rft.spage=581837&rft.pages=581837-&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2020.581837&rft_dat=%3Cproquest_doaj_%3E2464605807%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c531t-26002fc5d896da4588aa3685737012008b7a57c080ce4a7fbbf60beffabd3c533%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2464605807&rft_id=info:pmid/33240090&rfr_iscdi=true